A Phase 2, Multicenter, Open-Label, Single Arm, Two-Stage Study to Evaluate the Efficacy and Safety of CC-4047 (Pomalidomide) in Patients With Advanced Soft Tissue Sarcomas Who Have Relapsed or Are Refractory to Systemic Anticancer Therapy.
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2016
At a glance
- Drugs Pomalidomide (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 15 Apr 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 12 Aug 2009 Actual patient number (7) added as reported by ClinicalTrials.gov.
- 12 Aug 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.